Profound Medical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	8.41	6.37	2.44	0.39	2	3.15
Other Revenue	10.4	9.73	8.24	6.81	4.68	3.72
Revenue	18.81	16.1	10.68	7.2	6.68	6.87
Revenue Growth (YoY)	58.61%	50.73%	48.35%	7.75%	-2.79%	-5.90%
Cost of Revenue	5.44	4.71	3.64	2.89	3.66	3.92
Gross Profit	13.37	11.39	7.04	4.31	3.02	2.95
Selling, General & Admin	30.43	32.05	23.13	18.54	17.93	17.97
Research & Development	21.05	20.6	16.97	14.42	14.69	15.28
Operating Expenses	51.48	52.65	40.1	32.96	32.62	33.24
Operating Income	-38.11	-41.25	-33.06	-28.65	-29.6	-30.29
Interest Expense	-	-	-	-	-0.17	-0.07
Interest & Investment Income	1.07	1.07	1.44	0.78	0.8	0.21
Currency Exchange Gain (Loss)	-1.56	-2.13	3.81	-0.58	3.1	-0.29
Other Non Operating Income (Expenses)	-0.07	-	-	-	0.02	-0.16
EBT Excluding Unusual Items	-38.66	-42.32	-27.82	-28.45	-25.86	-30.59
Impairment of Goodwill	-	-	-	-	-2.52	-
Pretax Income	-38.66	-42.32	-27.82	-28.45	-28.38	-30.59
Income Tax Expense	0.24	0.25	-0	-0.13	0.29	0.11
Net Income	-38.9	-42.57	-27.82	-28.32	-28.67	-30.7
Net Income to Common	-38.9	-42.57	-27.82	-28.32	-28.67	-30.7
Shares Outstanding (Basic)	32	30	25	21	21	20
Shares Outstanding (Diluted)	32	30	25	21	21	20
Shares Change (YoY)	21.35%	22.08%	16.91%	1.69%	1.79%	18.33%
EPS (Basic)	-1.22	-1.41	-1.12	-1.34	-1.38	-1.50
EPS (Diluted)	-1.22	-1.41	-1.12	-1.34	-1.38	-1.50
Free Cash Flow	-38.68	-38.38	-23.45	-22.61	-25.8	-22.39
Free Cash Flow Per Share	-1.22	-1.27	-0.95	-1.07	-1.24	-1.09
Gross Margin	71.08%	70.77%	65.89%	59.90%	45.22%	42.95%
Operating Margin	-202.56%	-256.27%	-309.57%	-397.99%	-443.08%	-440.73%
Profit Margin	-206.76%	-264.44%	-260.45%	-393.43%	-429.11%	-446.66%
Free Cash Flow Margin	-205.61%	-238.43%	-219.60%	-314.06%	-386.17%	-325.80%
EBITDA	-37.61	-40.69	-32.13	-27.72	-28.83	-29.61
EBITDA Margin	-199.91%	-252.79%	-	-	-	-
D&A For EBITDA	0.5	0.56	0.94	0.93	0.78	0.68
EBIT	-38.11	-41.25	-33.06	-28.65	-29.6	-30.29
EBIT Margin	-202.56%	-256.27%	-	-	-	-
Revenue as Reported	18.81	16.1	10.68	7.2	6.68	6.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.